Search results

37 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
Timing could matter to how responsive cancer cells are to treatment, study suggests
In a new study published in Cell Systems, UNC Lineberger's Jeremy Purvis, PhD, and colleagues report that the timing of when DNA damage occurs within these different checkpoints matters to a cell’s fate.
Located in News
Using new knowledge about cell division, researchers look to improve chemotherapy effects
A study led by UNC Lineberger member Michael J. Emanuele, PhD, was featured on the cover of The Journal of Biological Chemistry. The researchers uncovered new details about a protein called NUSAP1 during chromosome segregation, and offered a possible way to sensitize cancer cells to a particular type of chemotherapy.
Located in News
To improve melanoma treatment, researchers look to block deletion of ‘self-reactive’ immune cells
UNC Lineberger researchers led by Maureen Su, MD, report on a potential new way to fight melanoma by blocking one of the immune system’s checks and balances.
Located in News
Located in Newsroom / UNC Lineberger in the News
Innovative cancer data resource expands, gains a new name
Academics and policymakers are using the Cancer Information & Population Health Resource, or CIPHR, to knit together data from multiple public and private sources to examine a wide range of complex issues tied to improving cancer outcomes in North Carolina.
Located in News
Study sheds light on why some breast cancers have limited response to immunotherapy
Jonathan Serody, MD, Benjamin Vincent, MD, and a team of UNC Lineberger investigators published findings in the Journal of Clinical Investigation that may explain why drugs designed to unleash the immune system against cancer were ineffective in treating a type of triple negative breast cancer. They determined “claudin-low” tumors were releasing a chemical signal to attract regulatory T-cells, which prevented the immune system from rejecting the cancer.
Located in News
Kim senior authors study in JCO Precision Oncology
William Y. Kim, MD, has published a study in JCO Precision Oncology that uncovered possible treatment approaches for urachal adenocarcinoma, a rare bladder cancer.
Located in Newsletters / / Honors and Awards / 2017
Using ‘sticky’ nanoparticles, researchers develop new strategy to boost body’s cancer defenses
In the journal Nature Nanotechnology, UNC Lineberger researchers led by Andrew Wang, MD, report on strides made in the development of a strategy to improve the immune system's detection of cancer proteins by using “sticky” nanoparticles.
Located in News
New models of kidney cancer may drive immunotherapy research
UNC Lineberger member William Y. Kim, MD, and his colleagues report in the journal Nature Communications they have created laboratory models of both papillary and clear cell renal cell carcinoma that faithfully mimic the genetic changes seen in tumors of patients with these cancers.
Located in News
UNC-Chapel Hill spinout company generates more than $108M in stock offering
Founded with support from KickStart Venture Services, a UNC-Chapel Hill program that works to turn University research into new companies, G1 Therapeutics is developing novel therapeutics based on discoveries at UNC Lineberger Comprehensive Cancer Center.
Located in News